You are here
The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.
SBC: Zymeron Corporation Topic: CBD181004
Nerve agents exert their toxic effect by binding to and inactivating enzyme acetylcholinesterase, a key enzymatic regulator of cholinergic neurotransmission. The binding becomes irreversible after a varying amount of time with nerve agents and this aging process limits the treatment window of oxime reactivators. To enhance the current antidote treatment of nerve agent autoinjectors, a pyridostigmi ...SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
SBC: AGAVE BIOSYSTEMS INC. Topic: CBD08103
Shelter enclosures for military working dogs in the event of a CB attack is a technology gap identified by the Joint Requirements Office. Important parameters to consider in the design of protective enclosures include low weight and size to minimize transport requirements; rapid setup; and accommodation of canine physiological and psychological comfort needs while providing protection against CB ...SBIR Phase II 2009 Department of DefenseOffice for Chemical and Biological Defense